Want to see FR:ALCRB full AI Analyst Report?
Top Page
Carbios SA
(ALCRB)
Select Model
Select Model
Rating:50Neutral
Price Target:
€5.50
▼(-14.73% Downside)
Action:Reiterated
Date:07/24/26
The score is held back primarily by persistent large operating losses and ongoing negative operating/free cash flow despite strong revenue growth. A comparatively well-capitalized, low-debt balance sheet provides meaningful support, while technicals show only moderate improvement (near-term strength but longer-term downtrend) and valuation is difficult to justify due to negative earnings and no dividend.
Positive Factors
Strong Revenue Growth
The sharp increase in revenue indicates meaningful progress in commercial activity and technology monetization. If this expansion continues, a larger revenue base could improve operating leverage, support partner adoption, and provide a stronger foundation for eventual margin recovery.
Negative Factors
Severe Operating Losses
Large operating and net losses show that current revenue remains far below the level needed to cover the company’s cost base. Persistent losses can delay self-funded growth, increase reliance on financing, and weaken the economic value of otherwise strong revenue expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
The sharp increase in revenue indicates meaningful progress in commercial activity and technology monetization. If this expansion continues, a larger revenue base could improve operating leverage, support partner adoption, and provide a stronger foundation for eventual margin recovery.
Read all positive factors
Carbios SA (ALCRB) vs. iShares MSCI France ETF (EWQ)
Market Cap
€93.64M
Dividend YieldN/A
Average Volume (3M)17.57K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees91
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-2.03
Shares Outstanding16,905,630
10 Day Avg. Volume16,976
30 Day Avg. Volume17,568
Financial Highlights & Ratios
PEG Ratio-1.81
Price to Book (P/B)0.97
Price to Sales (P/S)60.79
P/FCF Ratio-10.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.12
Revenue Forecast (FY)€6.00M
Carbios SA Business Overview & Revenue Model
Company Description
Carbios SAS, a pioneering French green chemistry company, is at the forefront of developing industrial bioprocesses for the biodegradation and biorecycling of various polymers. Among its key innovations is EVANESTO, an enzymatic solution specifica...
How the Company Makes Money
Carbios generates (or aims to generate, as technologies are scaled) revenue primarily by monetizing its proprietary enzymatic recycling technologies and associated know-how. Key revenue streams include: (1) Licensing and royalties: Carbios can lic...
Carbios SA Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
66
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.10M | 136.00K | 24.00K | 70.00K | 105.00K |
| Gross Profit | -16.56M | 96.00K | 24.00K | 70.00K | 105.00K |
| EBITDA | -21.40M | -32.29M | -18.73M | -20.73M | 5.29M |
| Net Income | -34.26M | -33.11M | -27.22M | -27.74M | 3.78M |
Balance Sheet | |||||
| Total Assets | 232.49M | 279.98M | 302.01M | 183.96M | 178.73M |
| Cash, Cash Equivalents and Short-Term Investments | 49.96M | 93.11M | 191.82M | 100.56M | 104.96M |
| Total Debt | 31.65M | 45.67M | 48.62M | 46.01M | 20.29M |
| Total Liabilities | 38.27M | 80.31M | 67.69M | 58.52M | 32.00M |
| Stockholders Equity | 193.76M | 199.68M | 234.31M | 125.44M | 146.74M |
Cash Flow | |||||
| Free Cash Flow | -18.44M | -92.76M | -49.39M | -34.77M | -21.25M |
| Operating Cash Flow | -15.65M | -30.20M | -22.59M | -23.05M | -9.04M |
| Investing Cash Flow | -18.03M | -70.58M | -22.39M | -9.33M | -22.84M |
| Financing Cash Flow | 330.00K | -1.28M | 136.25M | 26.75M | 107.76M |
Carbios SA Technical Analysis
Negative
6.45
Price Trends
6.31
Negative
6.52
Negative
8.14
Negative
Market Momentum
-0.25
Positive
34.96
Neutral
27.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCRB, the sentiment is Negative. The current price of 6.45 is above the 20-day moving average (MA) of 6.03, above the 50-day MA of 6.31, and below the 200-day MA of 8.14, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 34.96 is Neutral, neither overbought nor oversold. The STOCH value of 27.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALCRB.
Carbios SA Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | €105.88B | 28.50 | 13.42% | 1.84% | -1.30% | 3.05% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | €4.32B | 99.82 | 0.92% | 6.33% | -5.73% | -73.67% | |
57 Neutral | €81.47M | 21.57 | 7.97% | 1.36% | 6.27% | -0.96% | |
50 Neutral | €93.64M | -2.64 | -18.56% | ― | ― | ― | |
45 Neutral | €103.35M | -4.95 | -26.54% | ― | -20.58% | -41.43% |
* Basic Materials Sector Average
FR:ALCRB
Carbios SA
5.35
-4.00
-42.78%
FR:AI
Air Liquide
166.42
11.42
7.37%
FR:AKE
Arkema
56.90
2.02
3.68%
FR:ALAFY
AFYREN
2.63
0.10
3.75%
FR:ALBKK
Baikowski SA
22.00
3.23
17.20%
FR:ALDUB
Encres Dubuit SA
2.04
-0.34
-14.29%
Carbios SA Corporate Events
Carbios delays financing timeline but stays committed to Longlaville biorecycling plant
Aug 3, 2026
Carbios has reaffirmed its plan to build a biorecycling plant in Longlaville, France, but says closing the project’s financing will take longer than initially expected. Some banking partners have already secured credit committee approval, re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.